Literature DB >> 33660202

Intermittent Hypoxia Activates N-Methyl-D-Aspartate Receptors to Induce Anxiety Behaviors in a Mouse Model of Sleep-Associated Apnea.

Yun Fan1, Mei-Chuan Chou2,3,4, Yen-Chin Liu5, Ching-Kuan Liu4,6, Chu-Huang Chen1,7, Shiou-Lan Chen8,9.   

Abstract

Sleep apnea disrupts physiologic homeostasis and causes neuronal dysfunction. In addition to signs of mental disorders and cognitive dysfunction, patients with sleep apnea have a higher anxiety rate. Here, we examined the mechanisms underlying this critical health issue. We used a mouse model with sleep-associated chronic intermittent hypoxia (IH) to verify the effects of sleep apnea on neuronal dysfunction. To evaluate how IH alters neuronal function to yield anxiety-like behavior and cognitive dysfunction, we examined synaptic plasticity and neuronal inflammation in related brain areas, including the medial prefrontal cortex (mPFC), striatum, and hippocampus. Mice subjected to chronic IH for 10 days exhibited significant anxiety-like behaviors in the elevated plus maze test. IH mice spent less travel time in open arms and more travel time in enclosed arms compared to control mice. However, cognitive impairment was minimal in IH mice. Increased glutamate N-methyl-D-aspartate (NMDA) receptor subunits 2B (GluN2B) and phosphorylated-ERK1/2 were seen in the mPFC, striatum, and hippocampus of IH mice, but no significant microglial and astrocyte activation was found in these brain areas. Chronic IH in mice induced compensatory increases in GluN2B to disturb neuronal synaptic plasticity, without neuronal inflammation. The altered synaptic plasticity subsequently led to anxiety-like behavior in mice. Treatment with the NMDA receptor antagonist dextromethorphan attenuated chronic IH-induced anxiety-like behavior and GluN2B expression. Our findings provide mechanistic evidence of how IH may provoke anxiety and support for the importance of early intervention to alleviate anxiety-associated complications in patients with chronic sleep apnea.

Entities:  

Keywords:  Anxiety; Cognitive dysfunction; Intermittent hypoxia (IH); NMDA receptor

Mesh:

Substances:

Year:  2021        PMID: 33660202     DOI: 10.1007/s12035-021-02321-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  36 in total

1.  OSA symptoms associated with and predictive of anxiety in middle-aged men: secondary analysis of NHANES data.

Authors:  April L Shapiro; Stacey Culp; Ilana R Azulay Chertok
Journal:  Arch Psychiatr Nurs       Date:  2014-02-27       Impact factor: 2.218

2.  Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

Authors:  John M Ringman; Li-Jung Liang; Yan Zhou; Sitaram Vangala; Edmond Teng; Sarah Kremen; David Wharton; Alison Goate; Daniel S Marcus; Martin Farlow; Bernardino Ghetti; Eric McDade; Colin L Masters; Richard P Mayeux; Martin Rossor; Stephen Salloway; Peter R Schofield; Jeffrey L Cummings; Virginia Buckles; Randall Bateman; John C Morris
Journal:  Brain       Date:  2015-02-15       Impact factor: 13.501

3.  Anxiety symptoms predicted decline in episodic memory in cognitively healthy older adults: A 3-year prospective study.

Authors:  Ada Wai Tung Fung; Joyce Sau Wa Lee; Allen Ting Chun Lee; Linda Chiu Wa Lam
Journal:  Int J Geriatr Psychiatry       Date:  2018-01-03       Impact factor: 3.485

4.  Association of psychiatric disorders and sleep apnea in a large cohort.

Authors:  Amir Sharafkhaneh; Nilgun Giray; Peter Richardson; Terry Young; Max Hirshkowitz
Journal:  Sleep       Date:  2005-11       Impact factor: 5.849

5.  Prevalence of anxiety disorders in community dwelling older adults in Hong Kong.

Authors:  Ada Wai Tung Fung; Wai-Chi Chan; Corine Sau-Man Wong; Eric Yu-Hai Chen; Roger Man-Kin Ng; Edwin Ho-Ming Lee; Wing-Chung Chang; Se-Fong Hung; Eric Fuk-Chi Cheung; Pak-Chung Sham; Helen Fung-Kum Chiu; Ming Lam; Tin-Po Chiang; Jim van Os; Joseph Tak-Fai Lau; Glyn Lewis; Paul Bebbington; Linda Chiu Wa Lam
Journal:  Int Psychogeriatr       Date:  2016-10-21       Impact factor: 3.878

Review 6.  Depression and anxiety in obstructive sleep apnea syndrome: a review.

Authors:  T Saunamäki; M Jehkonen
Journal:  Acta Neurol Scand       Date:  2007-09-14       Impact factor: 3.209

7.  Somatic syndromes, insomnia, anxiety, and stress among sleep disordered breathing patients.

Authors:  Tshering Amdo; Nadia Hasaneen; Morris S Gold; Avram R Gold
Journal:  Sleep Breath       Date:  2016-01-21       Impact factor: 2.816

Review 8.  [Current status of cognitive dysfunction in patients with obstructive sleep apnea hypopnea syndrome].

Authors:  X Tang; M Zhang; N Zhou; J Yan; L X Yang; G H Chen
Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2017-05-20

9.  Propofol attenuates intermittent hypoxia induced up-regulation of proinflammatory cytokines in microglia through inhibiting the activation of NF-Bκ/p38 MAPK signalling.

Authors:  Song Liu; Jin-Yuan Sun; Lian-Ping Ren; Kui Chen; Bo Xu
Journal:  Folia Neuropathol       Date:  2017       Impact factor: 2.038

10.  Quality of life in patients at first time visit for sleep disorders of breathing at a sleep centre.

Authors:  Serena Iacono Isidoro; Adriana Salvaggio; Anna Lo Bue; Salvatore Romano; Oreste Marrone; Giuseppe Insalaco
Journal:  Health Qual Life Outcomes       Date:  2013-12-12       Impact factor: 3.186

View more
  2 in total

1.  Dose-dependent phosphorylation of endogenous Tau by intermittent hypoxia in rat brain.

Authors:  Alexandria B Marciante; John Howard; Mia N Kelly; Juan Santiago Moreno; Latoya L Allen; Elisa J Gonzalez-Rothi; Gordon S Mitchell
Journal:  J Appl Physiol (1985)       Date:  2022-07-21

2.  Explicit memory, anxiety and depressive like behavior in mice exposed to chronic intermittent hypoxia, sleep fragmentation, or both during the daylight period.

Authors:  Clementine Puech; Mohammad Badran; Alexandra R Runion; Max B Barrow; Zhuanhong Qiao; Abdelnaby Khalyfa; David Gozal
Journal:  Neurobiol Sleep Circadian Rhythms       Date:  2022-10-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.